Development Pipeline

	Preclinical	Phase I	Phase II	Phase III	Marketed
Zevalin®	Zevalin has been approved in the United States for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL), including patients with rituximab refractory follicular NHL.
Pixantrone
OPAXIO™	In March 2008, we submitted and the EMEA accepted for review a marketing authorization application seeking European approval for OPAXIO™ on equivalent effectiveness (non-inferiority) and improved safety as a single-agent in first-line PS2 NSCLC patients.
Brostallicin

	Preclinical	Phase I	Phase II	Phase III	Marketed
Novel Platinum Complexes

Patients Respond to Cancer Therapy in Different Ways. So Do We.

There are different kinds of cancer. That’s why we develop different kinds of cancer therapy, with the goal of making cancer more treatable for individual patients.

Our cancer drug development pipeline includes a taxane, a new compound designed to treat cancers normally treated with anthracyclines, a DNA minor grove binding agent, and a radioimmunotherapy—each of which has the potential to treat a variety of cancer types.

Current Status

We have one product on the market, two product candidates in phase III clinical development, one in phase II clinical development, and other candidates in preclinical research. These products may address the therapeutic limitations of conventional cancer therapies.